Moderna’s mRNA Cancer Breakthrough | Business and Finance News

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded19 Aug 2026

Publisherfeeds.acast.com ↗

Handlerec:20070398

Show notes

Moderna’s stock rocketed 144% after breakthrough data from its mRNA cancer vaccine, Intismeran, showed it dramatically improves outcomes for melanoma patients when paired with Merck’s Keytruda — the first late-stage success for an mRNA cancer vaccine. This validates Moderna’s tech beyond COVID-19, reigniting hopes for profitability and sparking a historic year-up of 409%. While past volatility has been extreme, this surge signals a pivotal shift in how investors view the company — and could reshape cancer treatment across multiple tumor types. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/868173df4862981c

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.